In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

AstraZeneca & Daiichi Sankyo announce positive results from DESTINY-Breast09 phase III trial of Enhertu plus pertuzumab to treat HER2-positive metastatic breast cancer ...

AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ...